{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "H2PJWi1Gbg4i",
    "tags": []
   },
   "source": [
    "# **Submodule 3.1 - Drug Design Basics**\n",
    "\n",
    "## **Learning Objectives:**\n",
    "* To learn the basics of different types of drug design from structural biology\n",
    "* To analyze the enzyme binding cavity to design enzyme activity modulator drugs. Illustrate the example of enzyme-based drug design\n",
    "* To learn the basics of peptide-based drug design with illustration of example from CD2-CD58 protein-protein interaction.  \n",
    "* To learn the basics of receptor-based drug design with an example.\n",
    "\n",
    "## **Prerequisites:** \n",
    "<mark> ADD </mark>\n",
    "\n",
    "## **Introduction**\n",
    "In this module, users learn different types of drug design with examples, visualization, and tutorials. Enzyme-based drug design, receptor-based drug design, and peptide-based drug design (along with protein-protein interaction and drug design) are demonstrated. This module uses all the software and knowledge used in Modules 1 and 2 and combines this knowledge to study the design of drugs. This module requires Modules 1 and 2 as prerequisites if the users are unfamiliar with the analysis of protein structure, binding cavity, docking, and protein-protein interactions."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## **Key Biochemistry and Medicinal Chemistry Terms**\n",
    "\n",
    "- **Bioavailability:** The proportion of a drug that enters the circulation when introduced into the body\n",
    "- **Sensitivity:** The ability of a drug to correctly identify or affect the intended target\n",
    "- **Affinity:** The strength of binding between a drug and its target receptor\n",
    "- **Specificity:** The ability of a drug to correctly exclude non-target interactions\n",
    "- **Efficacy:** The maximum therapeutic effect a drug can produce\n",
    "- **Potency:** The amount of drug required to produce a specific effect\n",
    "- **Half-Life:** Time required for the concentration of a drug to reduce by half in the body\n",
    "\n",
    "## **Key Biochemistry and Medicinal Chemistry Metrics**\n",
    "- **EC50 (Half Maximal Effective Concentration):** The concentration of a drug that gives half-maximal response.(Potency)\n",
    "- **IC50 (Half Maximal Inhibitory Concentration):** The concentration of a drug that inhibits a biological process by 50% (Sensitivity)\n",
    "- **ED50 (Median Effective Dose):** The dose of a drug that produces a therapeutic response in 50% of the population\n",
    "- **LD50 (Median Lethal Dose):** The dose of a drug that is lethal to 50% of a test population\n",
    "- **TD50 (Median Toxic Dose):** The dose that produces toxic effects in 50% of the population\n",
    "- **Vmax (Maximum Velocity):** The maximum rate of an enzymatic reaction when the enzyme is fully saturated with substrate. It represents the point where all enzyme active sites are occupied, and the enzyme is working at its peak performance.\n",
    "- **Km (Michaelis Constant):** A measure of the substrate concentration at which the reaction rate is half of Vmax. It indicates the enzyme's affinity for the substrate:\n",
    "\n",
    "## **Receptors**\n",
    "In drug discovery we refer to any protein that is activated by a ligand result in signal for pharmacological action as receptor. Enzymes are also receptors. However, the general definition of receptor is a biological macromolecule in or on the surface of cells to which selective binding of a specific substance results in change in conformation causing a specific physiologic effect on cells or tissues. Many receptors have extracellular as well as intracellular domains\n",
    "\n",
    "<center><img src=\"images/receptor.png\" width=400 /></center><br><br>\n",
    "\n",
    "Receptors are the largest targets of drugs in the human body including G-protein protein coupled receptors, nuclear receptors and ion channels and transporter proteins.\n",
    "\n",
    "## **Ligand-Receptor Response Types** \n",
    "\n",
    "#### **Agonist**\n",
    "Produce a conformational change to initiate a signal that is coupled to a biological response. Agonistic drugs work by mimicking the natural messengers and can elicit a full biological response when bound to the receptor. They stabilize the active conformation of the receptor and typically demonstrate both high affinity and high efficacy. Examples include epinephrine binding to Î²-adrenergic receptors and morphine binding to opioid receptors.\n",
    "\n",
    "#### **Partial Agonist**\n",
    "Activate a receptor but cannot produce a maximal signaling effect equivalent to that of a full agonist even when all available receptors are occupied. They have lower efficacy than full agonists while potentially maintaining similar binding affinity. This property can be therapeutically useful when a submaximal response is desired or when blocking effects of full agonists in high concentrations. Examples include buprenorphine at opioid receptors and buspirone at serotonin receptors.\n",
    "\n",
    "#### **Antagonist**\n",
    "Bind to a receptor but do not produce the conformational change that initiates an intracellular signal. Antagonistic drugs work by blocking the receptor and preventing agonist binding. Generally, they decrease the receptor signal response by competing with endogenous or exogenous agonists. They can bind with high affinity but have zero efficacy. Examples include naloxone blocking opioid receptors and propranolol blocking Î²-adrenergic receptors.\n",
    "\n",
    "#### **Inverse agonist**\n",
    "Bind to the same receptor binding site as agonists but produce an opposite biological response. They stabilize the inactive conformation of the receptor and reduce any constitutive (baseline) activity. This is particularly important in receptors that show significant basal activity. They can demonstrate high binding affinity but produce negative efficacy. Examples include some antihistamines and certain benzodiazepine receptor ligands.\n",
    "\n",
    "<center><img src=\"images/receptor_response.png\" width=600 /></center><br><br>\n",
    "\n",
    "### **Receptor Isoforms/Subtypes**\n",
    "There are distinct variants for some receptors which share similar structural features and respond to the same endogenous ligand.For example, adrenergic receptors and subtypes, Î±1, Î±2 and subtypes of Î±1, Î±1A, Î±1B, Î±1D, Î±2A, Î±2B  and Î±2C. Similarly, Î²1, Î²2 and Î²3 <mark> did this get cut off?</mark>.\n",
    "\n",
    "1. Agonists of the Î²2 receptors are used in the treatment of asthma (relaxation of the smooth muscles of the bronchi).\n",
    "2. Antagonists of the Î²1 receptors are used in the treatment of hypertension and angina (slow heart and reduce force of contraction).\n",
    "3. Antagonists of the Î±1 receptors are known to cause lowering of the blood pressure (relaxation of smooth muscle and dilation of the blood vessels).\n",
    "\n",
    "For details of structural differences read the paper [Qu et al](https://doi.org/10.1016/j.celrep.2019.10.088.) (2019) in *Cell Reports*\n",
    "\n",
    "<center><img src=\"images/adrenergic_isoforms.png\" width=600 /></center><br><br>\n",
    "\n",
    "### **Receptor Drug Design Example** \n",
    "Around 1958 Sir James proposed and used isoprenaline as Î²-adrenoceptor-selective agonist as a template structure. A chlorine derivative dichloroisoprenaline was designed.  Isoprenaline was an agonist of Î²-adrenoreceptor, but dichloroisoprenaline was a partial agonist of Î²-adrenoreceptor. By modification of the structures practolol and pronethanol, were designed as the first Î²-blockers. However, these had severe side effects and hence a safer, more potent derivative, propranolol, was designed. Then again, selectivity was needed between Î²1 and Î²2 blockers, as Î²1 receptors have importance in hypertension, but Î²2 have importance in asthma. Practolol was designed based on the hydrogen bonding of the para position substitution at the aromatic ring.  Based on these structures and analysis of 3D structure of adrenergic receptors one can see that subtle changes in the protein 3D structure and binding surface/cavity, pharmacological activity and hence clinical application may vary.\n",
    "\n",
    "<center><img src=\"images/receptor_drugs.png\" width=600 /></center><br><br>\n",
    "\n",
    "Thus careful design of drug molecules with agonist or antagonist activity and selectivity is important. Small substitutions in receptor ligands can result in large changes in the recpetors specificity. For example, in the image above it shows substituting a hydroxyl group with a chlorine group can alter a ligand from being an agonist to a partial agonist. \n",
    "\n",
    "## **Enzymes**\n",
    "Enzymes are biological catalysts that accelerate chemical reactions in cells. In drug discovery, enzymes represent major therapeutic targets as their dysregulation often leads to disease states. Unlike typical receptors, enzymes bind substrates in specific active sites and convert them to products through chemical reactions. Understanding enzyme structure, function, and regulation is crucial for developing effective enzyme inhibitors as therapeutic agents.\n",
    "\n",
    "<mark> Enzyme Image </mark>\n",
    "\n",
    "Enzymes are the second largest group of drug targets after receptors, including proteins like kinases, proteases, and oxidoreductases. Drug design for enzyme targets focuses on mimicking natural substrates or transition states to achieve specific inhibition, including:\n",
    "\n",
    "#### **Enzyme Inhibition**:\n",
    "Enzyme inhibitors can be classified based on their mechanism of action and the nature of their interaction with the enzyme. The two main categories are reversible and irreversible inhibition, each with distinct therapeutic applications and considerations.\n",
    "\n",
    "- <u>Reversible Inhibition</u>: Characterized by non-covalent interactions between the inhibitor and enzyme, allowing the inhibitor to dissociate from the enzyme. The inhibition effect is concentration-dependent and can be reduced or eliminated by removing the inhibitor. These interactions typically involve hydrogen bonding, van der Waals forces, and ionic interactions. The type of inhibition (competitive, non-competitive, uncompetitive, or mixed) depends on where and how the inhibitor binds to the enzyme.\n",
    "\n",
    "- <u>Competitive Inhibition</u>: Occurs when the inhibitor binds to the enzyme's active site, directly competing with the substrate for binding. The inhibition can be overcome by increasing substrate concentration. These inhibitors often structurally resemble the natural substrate. Characterized by increased Km with no change in Vmax. Examples include methotrexate competing with folate for dihydrofolate reductase and statins competing with HMG-CoA for HMG-CoA reductase.\n",
    "\n",
    "- <u>Non-competitive Inhibition</u>: Binds to a site different from the active site (allosteric site), causing a conformational change that prevents substrate conversion to product. Cannot be overcome by increasing substrate concentration. Characterized by decreased Vmax with no change in Km. Examples include heavy metals binding to sulfhydryl groups in enzymes and certain blood pressure medications.\n",
    "\n",
    "- <u>Uncompetitive Inhibition</u>: Binds only to the enzyme-substrate complex, not to the free enzyme. This binding prevents product formation and substrate release. Results in decreased Vmax and decreased Km. Less common than competitive and non-competitive inhibition. Examples include inhibition of lactate dehydrogenase by oxalate or alkaline phosphatase by L-phenylalanine.\n",
    "\n",
    "- <u>Mixed Inhibition</u>: Combines aspects of competitive and non-competitive inhibition. The inhibitor can bind to both free enzyme and enzyme-substrate complex but with different affinities. Results in changes to both Vmax and Km. For example, ketoconazole, a mixed inhibitor, binds to the 5-Î± reductase enzyme, while palladium ion acts as a mixed inhibitor of oxidoreductase enzymes. *Note, in mixed inhibition, Km can increase (â†‘) or decrease (â†“) depending on relative affinities for free enzyme versus enzyme-substrate complex.*\n",
    "\n",
    "<center><img src=\"images/kinetics_table.png\" width=400 /></center><br><br>\n",
    "\n",
    "\n",
    "- <u>Irreversible Inhibition</u>: Forms permanent covalent bonds with the enzyme, leading to permanent inactivation. Often requires the enzyme's catalytic mechanism to activate the inhibitor. Shows time-dependent inhibition and requires new enzyme synthesis for activity restoration. Examples include penicillin binding to bacterial transpeptidase and the acetylation of cyclooxygenase by aspirin.\n",
    "\n",
    "<center><img src=\"images/penicillin.png\" width=800 /></center><br><br>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "-------------------\n",
    "\n",
    "# ðŸ“Š Tutorials\n",
    "In these tutorials, we will use the PyMOL, ClusPro, and other cheminformatic tools to work through <u>**two**</u> applied activities to:\n",
    "- Compare ligand binding sites of two different receptors.\n",
    "- Visualize covalent bonding."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## ðŸŒŸ **Activity 1: Compare Binding Sites of Alpha and Beta Adrenergic Receptors**\n",
    "In this activity, you will compare the binding sites of the *alpha-adrenergic receptor* and *beta-adrenergic receptor*.\n",
    "\n",
    "### **Objectives**:\n",
    "Using their structures, identify differences between *alpha-adrenergic receptor* and *beta-adrenergic receptor* that can aid in designing selective drugs.\n",
    "\n",
    "### **Steps to Complete Activity**\n",
    "\n",
    "#### **Step 1: Fetch the Structures**\n",
    "1. Fetch both receptor structures in PyMOL:<br>\n",
    "   `PyMOL> fetch 9CBL  #PDB ID for Alpha-adrenergic receptor`<br>\n",
    "   `PyMOL> fetch 7BU6  #PDB ID for Beta-adrenergic receptor`\n",
    "\n",
    "#### **Step 2: Align the Structures**\n",
    "1. Align the helical regions of `9CBL` to `7BU6`: <br>\n",
    "   `9CBL > A > align > to molecule > 7BU6`\n",
    "2. If the molecules go out of the display window, navigate to the top menu:<br>\n",
    "     `Zoom > Visible`\n",
    "   - Both aligned molecules should now be displayed.\n",
    "\n",
    "#### **Step 3: Visualize Ligand Sites**\n",
    "1. Zoom in on the ligand site residues of `9CBL`:<br>\n",
    "   `9CBL > A > ligand site > cartoon`\n",
    "\n",
    "2. Zoom in on the ligand site residues of `7BU6`:<br>\n",
    "   `7BU6 > A > ligand site > cartoon`\n",
    "\n",
    "#### **Step 4: Highlight Differences**\n",
    "1. Color `9CBL` (alpha-2A adrenergic receptor) in green:<br>\n",
    "     `9CBL > C > green`\n",
    "     \n",
    "2. Color `7BU6` (beta-1 adrenergic receptor) in hot pink:<br>\n",
    "     `7BU6 > C > magenta > hotpink`\n",
    "\n",
    "3. In `7BU6`, select *N1363 (Asn1363)* and display the residue as sticks:<br>\n",
    "     `PyMOL> select 7BU6/N1363`<br>\n",
    "     `PyMOL> show sticks`\n",
    "\n",
    "4. In `9CBL`, select *F427 (Phe427)* and display the residue as sticks:<br>\n",
    "     `PyMOL> select 9CBL/F427`<br>\n",
    "     `PyMOL> show sticks`\n",
    "\n",
    "#### **Step 5: Analyze the Binding Interactions**\n",
    "<mark> I am confused whether this is just being pointed out or whether you want the user to highlight these residues as well following methodology presented above. I would be more clear. Could be optional.</mark>\n",
    "1. **Hydrophobic residues in `9CBL`**:\n",
    "   `F427 (Phe427)` is a hydrophobic residue.\n",
    "   Additional hydrophobic residues near the ligand:\n",
    "     ```\n",
    "     F404, Y431\n",
    "     ```\n",
    "\n",
    "2. **Interactions in `7BU6`**:\n",
    "   `N1363 (Asn1363)` forms a **hydrogen bond** with the ligand.\n",
    "   Hydrophobic residues near the ligand:\n",
    "     ```\n",
    "     W1337, F1340, Y1367\n",
    "     ```\n",
    "\n",
    "### **Alternative Method for Activity 1 - Write and Load PML Script**:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Run PML Script:\n",
    "with open(\"3.1 Adrenergic_Receptor_Comparison.pml\", \"w\") as scriptout:\n",
    "\n",
    "    # Step 1: Fetch the Structures\n",
    "    scriptout.write(\"fetch 9CBL, alpha_receptor, async=0\\n\")  # Fetch alpha-adrenergic receptor structure\n",
    "    scriptout.write(\"fetch 7BU6, beta_receptor, async=0\\n\")  # Fetch beta-adrenergic receptor structure\n",
    "    scriptout.write(\"hide everything, all\\n\")  # Hide all default representations\n",
    "    scriptout.write(\"show cartoon, all\\n\")  # Show both receptors in cartoon representation\n",
    "    scriptout.write(\"color green, alpha_receptor\\n\")  # Color alpha receptor green\n",
    "    scriptout.write(\"color hotpink, beta_receptor\\n\")  # Color beta receptor hot pink\n",
    "    scriptout.write(\"zoom all\\n\")  # Zoom to fit both receptors\n",
    "\n",
    "    # Step 2: Align the Structures\n",
    "    scriptout.write(\"align alpha_receptor and name CA, beta_receptor and name CA\\n\")  # Align alpha to beta receptor\n",
    "    scriptout.write(\"zoom all\\n\")  # Adjust view to see both structures\n",
    "\n",
    "    # Step 3: Visualize Ligand Sites\n",
    "    scriptout.write(\"select alpha_ligand_site, alpha_receptor and (byres all within 5 of resn LIG)\\n\")  # Select ligand site of alpha receptor\n",
    "    scriptout.write(\"select beta_ligand_site, beta_receptor and (byres all within 5 of resn E5E)\\n\")  # Select ligand site of beta receptor\n",
    "    scriptout.write(\"show sticks, alpha_ligand_site\\n\")  # Show ligand site residues as sticks for alpha receptor\n",
    "    scriptout.write(\"show sticks, beta_ligand_site\\n\")  # Show ligand site residues as sticks for beta receptor\n",
    "    scriptout.write(\"color yellow, alpha_ligand_site\\n\")  # Color alpha ligand site residues yellow\n",
    "    scriptout.write(\"color cyan, beta_ligand_site\\n\")  # Color beta ligand site residues cyan\n",
    "    scriptout.write(\"zoom alpha_ligand_site or beta_ligand_site\\n\")  # Focus on ligand sites\n",
    "\n",
    "    # Step 4: Highlight Specific Residues\n",
    "    scriptout.write(\"select alpha_key_residues, alpha_receptor and resi 404+427+431\\n\")  # Hydrophobic residues in alpha receptor\n",
    "    scriptout.write(\"select beta_key_residues, beta_receptor and resi 1337+1340+1363+1367\\n\")  # Key residues in beta receptor\n",
    "    scriptout.write(\"show sticks, alpha_key_residues\\n\")  # Show key residues in alpha receptor as sticks\n",
    "    scriptout.write(\"show sticks, beta_key_residues\\n\")  # Show key residues in beta receptor as sticks\n",
    "    scriptout.write(\"color orange, alpha_key_residues\\n\")  # Color key residues in alpha receptor orange\n",
    "    scriptout.write(\"color magenta, beta_key_residues\\n\")  # Color key residues in beta receptor magenta\n",
    "\n",
    "    # Step 5: Display Specific Residues\n",
    "    scriptout.write(\"select alpha_phe427, alpha_receptor and resi 427\\n\")  # Select Phe427 in alpha receptor\n",
    "    scriptout.write(\"select beta_asn1363, beta_receptor and resi 1363\\n\")  # Select Asn1363 in beta receptor\n",
    "    scriptout.write(\"show sticks, alpha_phe427\\n\")  # Show Phe427 as sticks\n",
    "    scriptout.write(\"show sticks, beta_asn1363\\n\")  # Show Asn1363 as sticks\n",
    "    scriptout.write(\"color red, alpha_phe427\\n\")  # Color Phe427 red\n",
    "    scriptout.write(\"color blue, beta_asn1363\\n\")  # Color Asn1363 blue\n",
    "\n",
    "    # Step 6: Save Visualization Outputs\n",
    "    scriptout.write(\"zoom all\\n\")  # Adjust zoom to fit everything\n",
    "    scriptout.write(\"png adrenergic_receptor_comparison.png, dpi=300\\n\")  # Save high-resolution PNG\n",
    "    scriptout.write(\"save adrenergic_receptor_comparison_session.pse\\n\")  # Save PyMOL session for future use\n",
    "\n",
    "    # Notes for the user\n",
    "    scriptout.write(\"# This script compares alpha (9CBL) and beta (7BU6) adrenergic receptor ligand binding sites.\\n\")\n",
    "    scriptout.write(\"# Hydrophobic interactions dominate in 9CBL, while hydrogen bonding and hydrophobic interactions are present in 7BU6.\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### **Key Insights**:\n",
    "- The <u>hydrophobic interactions</u> dominate in the alpha-adrenergic receptor (`9CBL`), while the beta-adrenergic receptor (`7BU6`) has a combination of *hydrophobic* and *hydrogen bonding* interactions.\n",
    "- These differences in binding sites can be exploited to design *selective drugs* for alpha- and beta-adrenergic receptors."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "r8GDFpmjmPXs"
   },
   "source": [
    "------------\n",
    "## ðŸŒŸ **Activity 2: Visualizing Covalent Binding Using PyMOL (PDB ID: 4G5P)**\n",
    "In this activity, you will visualize the covalent binding of *EGFR kinase* with the drug *afatinib*.\n",
    "\n",
    "### **Objectives**:\n",
    "- Use PyMOL to visualize covalent enzyme : drug binding.\n",
    "\n",
    "### **Steps to Complete Activity**:\n",
    "\n",
    "#### 1. **Fetch the structure**: <br>\n",
    "   `PyMOL> fetch 4g5p`\n",
    "\n",
    "#### 2. **Prepare the structure**: <br>\n",
    "   `PyMOL> remove chain B    #The molecule contains two subunits. Display the sequence and remove one of the molecules (Chain B)` <br>\n",
    "   `PyMOL> remove solvent    #Remove water molecules`\n",
    "\n",
    "#### 3. **Apply visualization preset**: <br>\n",
    "   `A > preset > ligand site > cartoon`\n",
    "\n",
    "#### 4. **Highlight the covalent bond**: <br>\n",
    "   `PyMOL> select C797`\n",
    "\n",
    "#### 5. **Make C797 bond more visible**: <br>\n",
    "   `sele > S > sticks`<br>\n",
    "   `sele > L > label > residues`<br>\n",
    "   `sele > C > color > hotpink`\n",
    "\n",
    "### **Key Observations**:\n",
    "- The <u>ligand</u> (afatinib) is displayed in *sticks*.\n",
    "- Residue *C797* is highlighted in <u>pink</u>, indicating its role in forming a *covalent bond* with the afatinib drug molecule.\n",
    "- This visualization demonstrates how covalent inhibitors form a permanent bond with their target proteins, showcasing the structural and chemical interactions involved."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "---------------\n",
    "## **Conclusions**\n",
    "<mark> add content </mark>\n",
    "## **Clean Up**\n",
    "<div class=\"alert alert-block alert-warning\"> <b>Attention:</b> Remember to shutdown VM and delete any relevant resources</a>. </div>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "colab": {
   "authorship_tag": "ABX9TyOT6oAzRnqpZxB0F4/NifX+",
   "provenance": []
  },
  "environment": {
   "kernel": "conda-base-py",
   "name": "workbench-notebooks.m126",
   "type": "gcloud",
   "uri": "us-docker.pkg.dev/deeplearning-platform-release/gcr.io/workbench-notebooks:m126"
  },
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "conda-base-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
